Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart in Adults With Dermatomyositis
NCT06284954Phase 2Active, not recruiting
- Sponsor
- argenx
- Start
- Aug 2024
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of empasiprubart in dermatomyositis (DM), sponsored by argenx. Started Aug 2024; status: active, not recruiting.
02
Drugs
empasiprubart
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT06284954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284954.